These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24559559)

  • 1. Prophylactic papillomavirus vaccines.
    Ribeiro-Müller L; Müller M
    Clin Dermatol; 2014; 32(2):235-47. PubMed ID: 24559559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.
    Gersch ED; Gissmann L; Garcea RL
    Antivir Ther; 2012; 17(3):425-34. PubMed ID: 22293302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV vaccines to prevent cervical cancer and genital warts: an update.
    Dochez C; Bogers JJ; Verhelst R; Rees H
    Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV & HPV vaccination: issues in developing countries.
    Bharadwaj M; Hussain S; Nasare V; Das BC
    Indian J Med Res; 2009 Sep; 130(3):327-33. PubMed ID: 19901442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
    Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
    Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and prejudices of human papillomavirus vaccines in India.
    Das BC; Hussain S; Nasare V; Bharadwaj M
    Vaccine; 2008 May; 26(22):2669-79. PubMed ID: 18455843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation prophylactic HPV vaccines: successes and challenges.
    Tyler M; Tumban E; Chackerian B
    Expert Rev Vaccines; 2014 Feb; 13(2):247-55. PubMed ID: 24350614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prophylactic and therapeutic vaccination against human papillomavirus].
    Brun JL; Riethmuller D
    J Gynecol Obstet Biol Reprod (Paris); 2007 Nov; 36(7):631-41. PubMed ID: 17822860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for new human papillomavirus vaccines.
    Stanley M
    Curr Opin Infect Dis; 2010 Feb; 23(1):70-5. PubMed ID: 19926987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the role and function of L2, the minor capsid protein of papillomaviruses.
    Pereira R; Hitzeroth II; Rybicki EP
    Arch Virol; 2009; 154(2):187-97. PubMed ID: 19169853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
    Tomson TT; Roden RB; Wu TC
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus (HPV) vaccines: a Canadian update.
    Foerster V; Murtagh J
    Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.